Mechanism for the tissue distribution of grepafloxacin, a fluoroquinolone antibiotic, in rats. 2002

Takashi Suzuki, and Yukio Kato, and Hiroyuki Sasabe, and Minoru Itose, and Gohachiro Miyamoto, and Yuichi Sugiyama
Department of Drug Metabolism, Tokushima Research Institute, Otsuka Pharmaceutical Co, Ltd, Tokushima City, Japan.

This study was carried out to investigate the most important factor(s) governing the tissue distribution of grepafloxacin (GPFX), a fluoroquinolone antibiotic, in rats. The tissue-to-blood concentration ratio (K(p)) of GPFX at steady state during constant infusion was highest in the lung, followed by the pancreas, kidney, and spleen. After bolus injection, GPFX was efficiently taken up by most of the organs examined, the uptake clearance other than the lung being almost blood flow-limited. Approximately 10% of the intravenously injected dose was rapidly trapped by the lung, but GPFX distribution rapidly decreased within 30 s due to the washout by the plasma flow. Thus, the higher distribution of GPFX to the lung compared with the other organs cannot be accounted for by a difference in its uptake or efflux. Subcellular fractionation after the infusion indicated that GPFX is primarily distributed to the organelle fractions in most organs, 60% of lung-associated GPFX being recovered in the nucleus and plasma membrane fraction. Such subcellular distribution in the lung was proportional to the phosphatidylserine (PhS) content of each fraction. The steady-state K(p) value in each tissue in vivo also correlated with the tissue content of PhS. GPFX preferentially binds to PhS, compared with other phospholipids, and this binding was inhibited by weakly basic drugs, such as quinidine, imipramine, and propranolol, that have also been reported to bind to PhS. The association of GPFX with PhS synthase transformants of Chinese hamster ovary (CHO-K1) cells depends on the PhS content of each cell line, this association being also inhibited by basic drugs. These results suggest that binding of GPFX to PhS is the major determinant of the high distribution of GPFX to the lung.

UI MeSH Term Description Entries
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000890 Anti-Infective Agents Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. Anti-Infective Agent,Anti-Microbial Agent,Antimicrobial Agent,Microbicide,Microbicides,Anti-Microbial Agents,Antiinfective Agents,Antimicrobial Agents,Agent, Anti-Infective,Agent, Anti-Microbial,Agent, Antimicrobial,Agents, Anti-Infective,Agents, Anti-Microbial,Agents, Antiinfective,Agents, Antimicrobial,Anti Infective Agent,Anti Infective Agents,Anti Microbial Agent,Anti Microbial Agents
D014018 Tissue Distribution Accumulation of a drug or chemical substance in various organs (including those not relevant to its pharmacologic or therapeutic action). This distribution depends on the blood flow or perfusion rate of the organ, the ability of the drug to penetrate organ membranes, tissue specificity, protein binding. The distribution is usually expressed as tissue to plasma ratios. Distribution, Tissue,Distributions, Tissue,Tissue Distributions
D017207 Rats, Sprague-Dawley A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company. Holtzman Rat,Rats, Holtzman,Sprague-Dawley Rat,Rats, Sprague Dawley,Holtzman Rats,Rat, Holtzman,Rat, Sprague-Dawley,Sprague Dawley Rat,Sprague Dawley Rats,Sprague-Dawley Rats
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus
D019540 Area Under Curve A statistical means of summarizing information from a series of measurements on one individual. It is frequently used in clinical pharmacology where the AUC from serum levels can be interpreted as the total uptake of whatever has been administered. As a plot of the concentration of a drug against time, after a single dose of medicine, producing a standard shape curve, it is a means of comparing the bioavailability of the same drug made by different companies. (From Winslade, Dictionary of Clinical Research, 1992) AUC,Area Under Curves,Curve, Area Under,Curves, Area Under,Under Curve, Area,Under Curves, Area

Related Publications

Takashi Suzuki, and Yukio Kato, and Hiroyuki Sasabe, and Minoru Itose, and Gohachiro Miyamoto, and Yuichi Sugiyama
January 2003, Drug metabolism and pharmacokinetics,
Takashi Suzuki, and Yukio Kato, and Hiroyuki Sasabe, and Minoru Itose, and Gohachiro Miyamoto, and Yuichi Sugiyama
January 1998, The Medical letter on drugs and therapeutics,
Takashi Suzuki, and Yukio Kato, and Hiroyuki Sasabe, and Minoru Itose, and Gohachiro Miyamoto, and Yuichi Sugiyama
February 1995, Antimicrobial agents and chemotherapy,
Takashi Suzuki, and Yukio Kato, and Hiroyuki Sasabe, and Minoru Itose, and Gohachiro Miyamoto, and Yuichi Sugiyama
January 2004, Arzneimittel-Forschung,
Takashi Suzuki, and Yukio Kato, and Hiroyuki Sasabe, and Minoru Itose, and Gohachiro Miyamoto, and Yuichi Sugiyama
March 1998, The Journal of pharmacology and experimental therapeutics,
Takashi Suzuki, and Yukio Kato, and Hiroyuki Sasabe, and Minoru Itose, and Gohachiro Miyamoto, and Yuichi Sugiyama
May 1999, The Journal of antimicrobial chemotherapy,
Takashi Suzuki, and Yukio Kato, and Hiroyuki Sasabe, and Minoru Itose, and Gohachiro Miyamoto, and Yuichi Sugiyama
September 2003, Comparative biochemistry and physiology. Toxicology & pharmacology : CBP,
Takashi Suzuki, and Yukio Kato, and Hiroyuki Sasabe, and Minoru Itose, and Gohachiro Miyamoto, and Yuichi Sugiyama
April 2001, Drug metabolism and disposition: the biological fate of chemicals,
Takashi Suzuki, and Yukio Kato, and Hiroyuki Sasabe, and Minoru Itose, and Gohachiro Miyamoto, and Yuichi Sugiyama
April 1995, The Journal of antimicrobial chemotherapy,
Takashi Suzuki, and Yukio Kato, and Hiroyuki Sasabe, and Minoru Itose, and Gohachiro Miyamoto, and Yuichi Sugiyama
January 2002, Japanese journal of pharmacology,
Copied contents to your clipboard!